These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16979891)

  • 1. Inequalities in oncology care: Economic consequences of high cost drugs.
    Niezen MG; Stolk EA; Steenhoek A; Uyl-De Groot CA
    Eur J Cancer; 2006 Nov; 42(17):2887-92. PubMed ID: 16979891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost of medications in the oncology sector in the context of health economics].
    Walter E; Batista A
    Wien Med Wochenschr; 2008; 158(7-8):227-33. PubMed ID: 18500477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rising costs of drugs in hospitals in the period 1996-2000 and over the next few years].
    Breekveldt-Postma NS; Zwart-van Rijkom JE; Egberts AC; Leufkens HG; Herings RM
    Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2547-51. PubMed ID: 12532669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nominal and real effects of hospital global budgets in France.
    Redmon DP; Yakoboski PJ
    Inquiry; 1995; 32(2):174-83. PubMed ID: 7601515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Refining the French system of cost assessment for oncology patients following chemotherapy].
    Lévy-Piedbois C; Borella L; Bergerot P; Peuvrel P; Erard C; Parmentier G; Ravaud A; Trombert Paviot B; Armand JP; Rodrigues JM
    Bull Cancer; 2003 Nov; 90(11):989-96. PubMed ID: 14706903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [[How to finance chemotherapy with new cancer drugs?].
    Livartowski A; Beuzeboc P; Le Vu B; Courbard M; Pierga JY; Extra JM; Scholl S; Pouillart P
    Bull Cancer; 2000 Oct; 87(10):745-54. PubMed ID: 11084538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 11. Escalating costs for cancer chemotherapy.
    Nyman JV; Dorr RT; Hall GR
    Am J Hosp Pharm; 1981 Aug; 38(8):1151-4. PubMed ID: 7270558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost issues in new disease-modifying treatments for advanced cancer: in-depth interviews with physicians.
    de Kort SJ; Kenny N; van Dijk P; Gevers S; Richel DJ; Willems DL
    Eur J Cancer; 2007 Sep; 43(13):1983-9. PubMed ID: 17616456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of health care services in the treatment of cancer.
    Ilbery PL
    Aust Fam Physician; 1978 Aug; 7(8):1062-74. PubMed ID: 101189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 16. [National cancer fund (Koningin Wilhelmina Fonds) justifiably calls for continued focus on the cancer problem in Netherlands].
    Pinedo HM; van Groeningen CJ
    Ned Tijdschr Geneeskd; 1999 Jul; 143(29):1499-502. PubMed ID: 10443270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic effects of "molecular" medicine].
    Riemann JF
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
    [No Abstract]   [Full Text] [Related]  

  • 18. Using burden of disease/cost-effectiveness as an instrument for district health planning: experiences from Uganda.
    Jeppsson A; Okuonzi SA; Ostergren PO; Hagström B
    Health Policy; 2004 Dec; 70(3):261-70. PubMed ID: 15488993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Methodology of pharmacoeconomic studies in oncology].
    Ballatori E
    Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost of cancer in France: pharmaceutical expenditure as part of global patients' care].
    Zambrowski JJ
    Bull Cancer; 2008 May; 95(5):535-41. PubMed ID: 18541518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.